Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

NEW YORK, NY--(Marketwired - Jul 7, 2014) - Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO...
June 20, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment

NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational...
June 12, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers

NEW YORK, NY--(Marketwired - Jun 12, 2014) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech...
June 04, 2014 08:30 ET | Source: Nuvilex, Inc.

Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview

NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
May 23, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients

NEW YORK, NY--(Marketwired - May 23, 2014) - Nuvilex (OTCQB: NVLX) is calling it a "two pronged attack" on pancreatic cancer, but investors may be calling it an "end-around" or another avenue of...
May 07, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials

NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA...
May 05, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist

NEW YORK, NY--(Marketwired - May 5, 2014) - Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer...
April 03, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist

NEW YORK, NY--(Marketwired - Apr 3, 2014) - That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it...
February 21, 2014 09:00 ET | Source: Nuvilex, Inc.

Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials

NEW YORK, NY--(Marketwired - Feb 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the...